US Stock MarketDetailed Quotes
RVNC Revance Therapeutics
- 3.800
- +0.070+1.88%
Close Nov 25 16:00 ET
- 3.800
- +0.000+0.01%
Post 18:54 ET
398.63MMarket Cap-1979P/E (TTM)
3.820High3.700Low1.55MVolume3.700Open3.730Pre Close5.87MTurnover1.61%Turnover RatioLossP/E (Static)104.90MShares9.74552wk High-2.45P/B366.49MFloat Cap2.30052wk Low--Dividend TTM96.44MShs Float42.410Historical High--Div YieldTTM3.22%Amplitude2.300Historical Low3.792Avg Price1Lot Size
About Revance Therapeutics Company
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
Company Profile
SymbolRVNC
Company NameRevance Therapeutics
Listing DateFeb 6, 2014
Issue Price16.00
Founded1999
CEOMr. Mark J. Foley
MarketNASDAQ
Employees597
Fiscal Year Ends12-31
Address1222 Demonbreun Street,Suite 2000
CityNashville
ProvinceTennessee
CountryUnited States of America
Zip Code37203
Phone1-615-724-7755
Websitehttp://www.revance.com
Company Executives
- Name
- Position
- Salary
- Mark J. Foley
- Director and Chief Executive Officer
- 10.07M
- Tobin C. Schilke
- Chief Financial Officer and Principal Accounting Officer
- 3.97M
- Dwight Moxie
- Chief Legal Officer
- 3.53M
- Erica Jordan
- Chief Commercial Officer
- --
- Dr. David A. Hollander, M.D.
- Chief Medical Officer and Global Therapeutics Franchise Lead
- --
- Angus Charles Russell
- Chairman of the Board
- 346.03K
- Julian S. Gangolli
- Independent Director
- 305.03K
- Jill Beraud
- Independent Director
- 317.53K
- Christian W. Nolet, C.P.A.
- Independent Director
- 315.03K
- Dr. Vlad Coric, M.D.
- Independent Director
- 421.49K
- Olivia C. Ware, M.B.A.
- Independent Director
- 295.03K
- Carey O’Connor Kolaja
- Independent Director
- 304.18K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data